Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.
Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.